

---

# *Diabetic Neuropathies: Current Treatment Strategies*

**Tuesday, November 9, 2004  
12:30 - 1:30 pm/1:30 - 2:30 pm/3:30 - 4:30 pm ET**

## Syllabus and Course Guide



**Joslin Diabetes Center**

**Satellite Broadcast CME Network**

**Joslin Diabetes FOCUS™**

**PRIMEDIA**  
H E A L T H C A R E

© Joslin Diabetes Center and PRIMEDIA Healthcare, 2004. This syllabus is designed to be used in conjunction with the facilitated satellite broadcast and VHS videotape activities titled, *Diabetic Neuropathies: Current Treatment Strategies* (EDA# 556-0040-05), by Joslin Diabetes Center and PRIMEDIA Healthcare. PRIMEDIA Healthcare is a division of PRIMEDIA Workplace Learning. This activity is supported by an unrestricted educational grant from Pfizer Inc.

---

# *Diabetic Neuropathies: Current Treatment Strategies*

## STATEMENT OF NEED

The comprehensive management of the patient with diabetes must transcend glucose management and extend to the prevention, early diagnosis, and aggressive treatment of its various complications, such as painful neuropathies. Today, new tools and methods for glucose control and preventive and treatment strategies can reduce severe visual impairment, amputations, and painful neuropathies. These advances markedly improve longevity and quality of life by reducing potential sequelae for millions of patients with diabetes. Primary care providers, who see the bulk of these patients, are in a unique position to implement these new preventive and treatment interventions and significantly improve outcomes.

This educational activity will explain the pathophysiology and natural history of diabetic neuropathies. It will outline current clinical approaches to managing these conditions, along with practical methods for the diagnosis and treatment of diabetic neuropathies and other microvascular complications such as renal and ophthalmologic disease in people with diabetes.

## LEARNING OBJECTIVES

Participants will be provided with evidence-based practical and clinically relevant information. At the completion of this activity, the participant should be able to:

- Recognize the clinical signs and symptoms of the spectrum of neuropathic complications seen in people with diabetes
- Prevent or diagnose the painful neuropathic complications of diabetes based on an understanding of their pathophysiology and clinical manifestations
- Diagnose and initiate treatment of autonomic neuropathies
- Treat patients with diabetic neuropathies using new, effective therapeutic modalities

## TARGET AUDIENCE

This accredited activity has been developed for primary care physicians, neurologists, nurse practitioners, physician assistants, nurses, pharmacists, and other clinicians who manage people with diabetes.

# *Diabetic Neuropathies: Current Treatment Strategies*

## CONTINUING EDUCATION (CE) INSTRUCTIONS

### ***CME Credit Instructions through Joslin Diabetes Center***

(CME credit is for physicians. Nurses, pharmacists and other medical professionals, see below for CNE/CPE credit.) Participants viewing this presentation are asked to please sign the **Joslin DiabetesFOCUS™** attendance sheet.

Successful completion of this activity includes the following:

- Review this syllabus and course guide.
- Participate in the satellite broadcast or videotape activity.
- After viewing the presentation, complete the 10-question posttest\* and credit application and evaluation form by one of the following methods:

Take the posttest, fill out the evaluation form and receive CME credit online on the Joslin Diabetes Center Professional Education Web site at [www.ProfessionalEd.joslin.org](http://www.ProfessionalEd.joslin.org). Under the WebCME activity listings, locate this activity, and register for the posttest. You will need to enter this passcode to complete your registration: **200405**. Participants who score 70% or higher on the posttest and complete the evaluation form online can immediately print out their certificate.

OR

Complete the **CME Credit Application & Evaluation for Physicians Form** (located in this syllabus), including your responses for the 10-question posttest; and submit the form to the address indicated for processing. Participants who score 70% or higher on the posttest and complete the evaluation form will receive a CME certificate of credit within 4 weeks following receipt of the form.

### ***CNE/CPE Credit Instructions through Primedia Healthcare***

(For nurses, pharmacists and other medical professionals). Participants viewing this presentation are asked to please sign the **Joslin DiabetesFOCUS™** attendance sheet.

Successful completion of this activity includes the following:

- Review this syllabus and course guide.
- Participate in the satellite broadcast or videotape activity.
- Complete the CE Credit Application & Evaluation Form (located in this syllabus), including the 10-question posttest.\*
- Submit forms to the address indicated for processing.
- Participants who successfully complete the posttest and CE Credit Application & Evaluation Form will receive a CE statement of credit within 4 weeks following receipt of the form.

There is no fee for participation in this activity.

The estimated time for completion is 60 minutes.

*\*Accreditation guidelines mandate that sponsors of continuing education provide a learning assessment mechanism (posttest) that allows participants to assess their achievement of an educational activity. Please be sure to complete the posttest section of the **CME or CE Credit Application & Evaluation Form** to receive continuing education credit.*

---

# *Diabetic Neuropathies: Current Treatment Strategies*

## **DISTINGUISHED FACULTY**

### ***Richard S. Beaser, MD – Moderator***

Dr. Beaser is Assistant Clinical Professor of Medicine at Harvard Medical School, Boston, Massachusetts. He is also Medical Executive Director of Professional Education at Joslin Diabetes Center in Boston. In addition to his recent academic contributions to the field, Dr. Beaser has served as Section Head of Adult Diabetology Practice, and Chief of Patient Education at the Joslin Diabetes Center, as well as Medical Director of the Diabetes Treatment Unit of the Joslin Diabetes Center and New England Deaconess Hospital. He has also served as a clinical investigator for many trials of diabetes treatment, notably the Diabetes Control and Complications Trial (DCCT). Dr. Beaser has authored or coauthored *The Joslin Diabetes Manual*, *Outsmarting Diabetes*, *The Joslin Guide to Diabetes*, and *Joslin's Diabetes Deskbook*.

### ***Vivian A. Fonseca, MD, MRCP***

Dr. Fonseca is Professor of Medicine, Tullis-Tulane Alumni Chair in Diabetes, and Chief of the Section of Endocrinology at Tulane University Medical Center in New Orleans, Louisiana. He is a Fellow of the American Association of Clinical Endocrinologists, The Royal College of Physicians (London) and the American College of Physicians. He is a member of The Endocrine Society, the American Diabetes Association (ADA), and International Diabetes Federation. Dr. Fonseca serves on the Clinical Practice Committee of the ADA (current Chairman) and the joint ADA/ACC "Make the Link Program." His current research interests include the prevention and treatment of diabetic complications and risk factor reduction in cardiovascular disease. Dr. Fonseca is Associate Editor of *Diabetes Care*, and is involved as a reviewer or editor for several other journal publications.

### ***Roy Freeman, MD***

Dr. Freeman is Associate Professor of Neurology at Harvard Medical School and Director of the Center for Autonomic and Peripheral Nerve Disorders in the Department of Neurology at Beth Israel Deaconess Medical Center in Boston, Massachusetts. Dr. Freeman's clinical and research expertise is in the physiology and pathophysiology of the autonomic nervous system and small nerve fibers. He is also an authority on the neurologic complications of diabetes, the diagnosis and treatment of autonomic and peripheral nervous system disorders, and neuropathic pain. He is also Chairman of the World Federation of Neurology research group on the autonomic nervous system. Dr. Freeman is the former President of the American Autonomic Society and former Chairman of the Autonomic Nervous System Section of the American Academy of Neurology. He is also the principal investigator on National Institutes of Health-funded studies on the pathophysiology of orthostatic intolerance, and hypoglycemia and the autonomic nervous system.

---

# *Diabetic Neuropathies: Current Treatment Strategies*

## **FACULTY DISCLOSURE STATEMENT**

**ACTIVITY NAME:** *Diabetic Neuropathies: Current Treatment Strategies*

**RELEASE DATE:** *November 9, 2004*

**ACTIVITY FORMAT:** *National Satellite Broadcast*

It is the policy of Joslin Diabetes Center to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty participating in CME activities sponsored by Joslin Diabetes Center are expected to present evidence-based data, identify and reference off-label product use, and disclose all relevant financial relationships existing within the past 12 months with those entities supporting the activity or any others whose products or services are discussed, including:

- any commercial product(s) or device(s)
- the manufacturer(s) of any commercial products or devices
- the provider(s) of any commercial services

If a faculty member has no information to disclose or refuses to do so, this information will also be provided.

The opinions and comments expressed in this activity are those of the speakers and should not be considered the opinions or comments of the Joslin Diabetes Center or PRIMEDIA Healthcare.

The faculty of this activity have disclosed the following:

- Dr. Beaser is a consultant for Amylin Pharmaceuticals, Aventis Pharmaceuticals, and Wyeth Pharmaceuticals.
- Dr. Fonseca has grant/research support from and is a consultant for Aventis Pharmaceuticals, Eli Lilly and Company, GlaxoSmithKline, Pfizer Inc, and Takeda Pharmaceuticals North America, Inc.
- Dr. Freeman has grant/research support from and is a consultant for Eli Lilly and Company, Ortho-McNeil Pharmaceutical, Inc., and Pfizer Inc. He also has grant/research support from Asta Medica, and is on the speakers bureau for Pfizer Inc and Shire US Inc.

# Diabetic Neuropathies: Current Treatment Strategies

## BIBLIOGRAPHY

- Brownlee M. Negative consequences of glycation. *Metabolism*. 2000;49(2 suppl 1):9-13.
- Boulton AJ, Kirsner RS, Vileikyte L. Neuropathic diabetic foot ulcers. *N Engl J Med*. 2004;351:48-55.
- Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. *Diabetes Care*. 2004;27:1458-1486.
- Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med*. 1993;329:977-986.
- Dyck PJ, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. *Muscle Nerve*. 2002;25:477-491.
- Ewing DJ, Campbell IW, Clarke BF. The natural history of diabetic autonomic neuropathy. *Q J Med*. 1980;49:95-108.
- Freeman R. Diabetic peripheral neuropathy. In Beaser RS, et al, eds. *Joslin's Diabetes Deskbook*. Boston, MA: Joslin Diabetes Center; 2001:417-440.
- Freeman R. The peripheral nervous system and diabetes. In: Kahn CR, Weir GC, King GL, et al, eds. *Joslin's Diabetes Mellitus*. 14th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:chap 57.
- Freeman R. Treatment of orthostatic hypotension. *Semin Neurol*. 2003;23:435-442.
- Gefen A, Chen J, Elad D. Stresses in the normal and diabetic human penis following implantation of an inflatable prosthesis. *Med Biol Eng Comput*. 1999;37:625-631.
- Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. *N Engl J Med*. 1998;338:1397-1404.
- Greene DA, Lattimer SA, Sima AA. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. *N Engl J Med*. 1987;316:599-606.
- Guay AT, Perez JB, Jacobson J, Newton RA. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. *Androl*. 2001;22:793-797.
- Klein R, Klein BE, Lee KE, Moss SE, Cruickshanks KJ. Prevalence of self-reported erectile dysfunction in people with long-term IDDM. *Diabetes Care*. 1996;19:135-141.
- Lepore G, Nosari I. Efficacy of oral sildenafil in the treatment of erectile dysfunction in diabetic men with positive response to intracavernosal injection of alprostadil. *Diabetes Care*. 2001;24:409-411.
- Litzelman DK, Slemenda CW, Langefeld CD, et al. Reduction of lower extremity clinical abnormalities in patients with non-insulin-dependent diabetes mellitus: a randomized, controlled trial. *Ann Intern Med*. 1993;119:36-41.
- McCulloch DK, Campbell IW, Wu FC, Prescott RJ, Clarke BF. The prevalence of diabetic impotence. *Diabetologia*. 1980;18:279-283.
- Miller TA. Diagnostic evaluation of erectile dysfunction. *Am Fam Physician*. 2000;61:95-104, 109-110.
- Moss SE, Klein R, Klein BE. The prevalence and incidence of lower extremity amputation in a diabetic population. *Arch Intern Med*. 1992;152:610-616.
- NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. *JAMA*. 1993;270:83-90.
- O'Brien IA, McFadden JP, Corral RJ. The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. *Q J Med*. 1991;79:495-502.
- Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. *Diabetes Res Clin Pract*. 1995;28:103-117.
- Romeo JH, Seftel AD, Madhun ZT, Aron DC. Sexual function in men with diabetes type 2: association with glycemic control. *J Urol*. 2000;163:788-791.
- Sampson MJ, Wilson S, Karagiannis P, Edmonds M, Watkins PJ. Progression of diabetic autonomic neuropathy over a decade in insulin-dependent diabetics. *Q J Med*. 1990;75:635-646.
- Shabsigh R, Klein LT, Seidman S, Kaplan SA, Lehrhoff BJ, Ritter JS. Increased incidence of depressive symptoms in men with erectile dysfunction. *Urology*. 1998;52:848-852.
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet*. 1998;352:837-853.
- Vinik AI, Erbas T, Stansberry KB, Pittenger GL. Small fiber neuropathy and neurovascular disturbances in diabetes mellitus. *Exp Clin Endocrinol Diabetes*. 2001;109(suppl 2):S451-S473.
- Vinik AI, Freeman R, Erbas T. Diabetic autonomic neuropathy. *Semin Neurol*. 2003;23:365-372.
- Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. *Diabetes Care*. 2003;26:1553-1579.
- Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. *Diabetologia*. 2000;43:957-973.

# *Diabetic Neuropathies: Current Treatment Strategies*

## **CME/CE CREDIT POSTTEST**

Participants must score 70% or higher on this posttest to receive credit. Please see Credit Information page for types of credit offered.

### **Diabetic Neuropathies: Current Treatment Strategies**

Activity EDA Number 556-0040-05

Please select only one answer to each question.

- 1. Types of diabetic neuropathy include:**
  - A. Proximal sensory loss
  - B. Weakness in the toes
  - C. Respiratory muscle weakness
  - D. Isolated cranial nerve paralysis
  - E. Night blindness/tunnel vision
- 2. Mechanisms involved in the development of diabetic neuropathy include:**
  - A. Sorbitol accumulation
  - B. Hypoglycemia
  - C. Hypokalemia
  - D. Nerve damage caused by hyperinsulinemia
  - E. Carbamylation of proteins
- 3. Clinical features of diabetic peripheral neuropathy include:**
  - A. Sensory loss in a "glove and stocking" distribution
  - B. Deep-seated pain
  - C. Wasting of the small muscles of hands and feet
  - D. Loss of balance
  - E. All of the above
- 4. Which of the following is an important consideration in the treatment of diabetic neuropathy?**
  - A. Good glycemic control leads to rapid reversal of neuropathy.
  - B. Good glycemic control may lead to a transient worsening of symptoms.
  - C. Symptoms of autonomic neuropathy cannot be corrected.
  - D. There is no approved treatment for sensory loss.
  - E. Neuropathy leads to cognitive dysfunction.
- 5. Cardiovascular autonomic neuropathy is associated with all but which of the following?**
  - A. Heart rate changes
  - B. Hypertension
  - C. Silent ischemia
  - D. Loss of circadian patterns
  - E. Exercise intolerance

---

## *Diabetic Neuropathies: Current Treatment Strategies*

### **CME/CE CREDIT POSTTEST**

6. **Diabetic amyotrophy is a:**
  - A. Myopathy
  - B. Myelopathy
  - C. Wasting syndrome
  - D. Muscular dystrophy
  - E. Neuropathy
7. **The enzyme that catalyzes the formation of sorbitol from glucose is:**
  - A. Sorbitol dehydrogenase
  - B. Protein kinase A
  - C. Hexokinase
  - D. Aldose reductase
  - E. Protein kinase C
8. **The prevalence of clinically evident generalized neuropathy after 25 years of diabetes is:**
  - A. 5%
  - B. 10%
  - C. 25%
  - D. 50%
  - E. 75%
9. **Which of the following is a feature of a small fiber neuropathy?**
  - A. Pain and temperature perception loss
  - B. Vibration and position perception loss
  - C. Areflexia
  - D. Weakness
  - E. Nerve conduction abnormalities
10. **Gabapentin and pregabalin bind to a subunit of which of the following channels?**
  - A. Potassium
  - B. Calcium
  - C. NMDA
  - D. Sodium
  - E. Magnesium



---

# *Diabetic Neuropathies: Current Treatment Strategies*

## **CREDIT INFORMATION**

This syllabus is designed to be used in conjunction with the facilitated satellite broadcast and videotape activity titled **Diabetic Neuropathies: Current Treatment Strategies** (EDA 556-0040-05), by Joslin Diabetes Center and PRIMEDIA Healthcare. PRIMEDIA Healthcare is a division of PRIMEDIA Workplace Learning.

### **PHYSICIANS**

The Joslin Diabetes Center, Boston, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. The Joslin Diabetes Center designates this educational activity for a maximum of 1.0 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity. This CME activity was planned and produced in accordance with ACCME Essentials.

### **NURSES**

This activity for 1.2 contact hours (1.4 for self-study) is provided by PRIMEDIA Healthcare, a division of PRIMEDIA Workplace Learning, which is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. Accreditation by the American Nurses Credentialing Center's Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product. This activity is also accredited for continuing nursing education in the following states which do not recognize ANCC credits: Alabama Board of Nursing (provider number ABNP0529), California Board of Registered Nursing (Provider approved by the California Board of Registered Nursing, Provider Number CEP10783, for 1.4 contact hours), Florida Board of Nursing (provider number FBN 2552).

### **PHARMACISTS**

PRIMEDIA Healthcare, a division of PRIMEDIA Workplace Learning, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.



CPE Credit: 1.0 contact hour or 0.10 CEUs

® Universal Program Number: 775-000-04-040-HO4 recorded/self-study

**For questions pertaining to the content of this activity, please contact Joslin Diabetes Center's Professional Education Office at 888-567-5460, or the Director of Education for PRIMEDIA Healthcare at 800-624-2272, ext. 5312.**

SATELLITE BROADCAST

# Diabetic Neuropathies: Current Treatment Strategies

## CME CREDIT APPLICATION & EVALUATION FORM FOR PHYSICIANS

Joslin Diabetes Center, Boston, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. The Joslin Diabetes Center designates this educational activity for a maximum of 1.0 category 1 credits toward the AMA Physician's Recognition Award.

**Joslin Diabetes Center offers two methods to receive CME credit. Your evaluation is necessary to receive continuing medical education credit and to assist in planning future activities.**

1. Take the posttest and fill out the evaluation form online to receive CME credit on the Joslin Diabetes Center Professional Education Web site at [www.ProfessionalEd.joslin.org](http://www.ProfessionalEd.joslin.org). Under the WebCME activity listings, locate this activity and register for the posttest. You will need to enter the following 6-digit passcode to complete your registration: **200405**.

OR

2. Take the posttest and fill out this CME Credit Application and Evaluation form to request CME credit by mail or fax. Please fill in the posttest responses and the appropriate squares on the rating scales in black or blue ink and return this application and evaluation form to: **PRIMEDIA Healthcare, 4101 International Parkway, Carrollton, TX 75007**  
Phone: (888) 466-3250. Fax: (972) 309-4580.

**PLEASE PRINT CLEARLY.**

Name (First, Middle Initial, Last): \_\_\_\_\_

Degree: \_\_\_\_\_ Date of Participation: \_\_\_\_\_

Affiliation: \_\_\_\_\_

Mailing Address: \_\_\_\_\_

City, State, Zip: \_\_\_\_\_

Telephone Number: \_\_\_\_\_ Fax Number: \_\_\_\_\_

E-mail Address: \_\_\_\_\_

Length of time to complete activity (hours): \_\_\_\_\_ (rounded to the nearest quarter hour)

### POSTTEST RESPONSES

Minimum score of 70% is required to pass and receive CME credit.

- |          |          |          |          |           |
|----------|----------|----------|----------|-----------|
| 1. _____ | 2. _____ | 3. _____ | 4. _____ | 5. _____  |
| 6. _____ | 7. _____ | 8. _____ | 9. _____ | 10. _____ |

Please indicate your professional credential: (choose only one)

- |                                    |   |  |  |                              |
|------------------------------------|---|--|--|------------------------------|
| <input type="checkbox"/> MD/DO     | <input type="checkbox"/> Nurse Practitioner | <input type="checkbox"/> Physician Assistant | <input type="checkbox"/> Nurse                       | <input type="checkbox"/> DPM |
| <input type="checkbox"/> Dietitian | <input type="checkbox"/> Pharmacist         | <input type="checkbox"/> CDE                 | <input type="checkbox"/> Other: Please specify _____ |                              |

Please indicate your area of practice specialty: (choose only one)

- |  |  |  |                                    |
|--|--|--|------------------------------------|
| <input type="checkbox"/> Family/General Medicine | <input type="checkbox"/> Internal Medicine           | <input type="checkbox"/> Endocrinology | <input type="checkbox"/> Neurology |
| <input type="checkbox"/> Nephrology              | <input type="checkbox"/> Other: Please specify _____ |  |                                    |

I perform most of my patient care in the following setting (choose only one):

- |   |   |  |
|---|---|--|
| <input type="checkbox"/> Inpatient hospital setting | <input type="checkbox"/> Managed care/HMO/group setting | <input type="checkbox"/> University/academic setting |
| <input type="checkbox"/> Private office             | <input type="checkbox"/> Other: Please specify _____    |  |

### OVERALL QUALITY OF PRESENTATION

Your prior knowledge of the topic  
Relevance to your educational needs  
Quality of presentation

High				Low
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

# Diabetic Neuropathies: Current Treatment Strategies

## ACTIVITY IN GENERAL

Please indicate your agreement or disagreement with the following statements.

- |   | Agree                    |                          |                          | Disagree                 |
|---|--------------------------|--------------------------|--------------------------|--------------------------|
|   | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 1. The activity met my educational needs.   | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 2. After participating in this activity, I am able to:  |                          |                          |                          |                          |
| • Recognize the clinical signs and symptoms of the spectrum of neuropathic complications seen in people with diabetes   | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| • Prevent or diagnose the painful neuropathic complications of diabetes based on an understanding of their pathophysiology and clinical manifestations  | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| • Diagnose and initiate treatment of autonomic neuropathies   | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| • Treat patients with diabetic neuropathies using new, effective therapeutic modalities   | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 3. The scope, depth, and level of activity content were appropriate.  | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 4. The content of the activity reflected a fair, balanced review of the selected topics.  | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 5. As a result of this activity, I will modify some aspect of managing patients with diabetes who are at risk for microvascular complications and who have diabetic neuropathy.                                       | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 6. If you would modify patient management, which of the following would be included? (choose all that apply)  |                          |                          |                          |                          |
| • Target recommended A1C goals more aggressively  |                          |                          |                          |                          |
| • Utilize the microalbumin measurement as a diagnostic tool   |                          |                          |                          |                          |
| • More aggressively treat hypertension in people with diabetes  |                          |                          |                          |                          |
| • Recommend regular ophthalmologic evaluations  |                          |                          |                          |                          |
| • Regularly screen for signs and symptoms of diabetic neuropathy more   |                          |                          |                          |                          |
| • More aggressively treat painful diabetic neuropathy   |                          |                          |                          |                          |
| • Other: _____  |                          |                          |                          |                          |
| 7. How many miles did you travel (one way) to attend this activity?   |                          |                          |                          |                          |
| <input type="checkbox"/> 0-10 <input type="checkbox"/> 11-20 <input type="checkbox"/> 21-30 <input type="checkbox"/> 31-40 <input type="checkbox"/> 41-50 <input type="checkbox"/> 51-60 <input type="checkbox"/> 60+ |                          |                          |                          |                          |
| 8. How did you hear about this activity? (choose all that apply)  |                          |                          |                          |                          |
| <input type="checkbox"/> Hospital notice <input type="checkbox"/> Colleague <input type="checkbox"/> Web site <input type="checkbox"/> Mail <input type="checkbox"/> Fax <input type="checkbox"/> E-mail              |                          |                          |                          |                          |
| <input type="checkbox"/> Journal ad <input type="checkbox"/> Telephone <input type="checkbox"/> Other: Please specify: _____  |                          |                          |                          |                          |
| 9. I selected this activity because of...(please choose all that apply)   |                          |                          |                          |                          |
| <input type="checkbox"/> Activity content <input type="checkbox"/> CME credit <input type="checkbox"/> It was a Joslin Diabetes Center activity   |                          |                          |                          |                          |
| <input type="checkbox"/> Location <input type="checkbox"/> Time and date <input type="checkbox"/> Speakers  |                          |                          |                          |                          |
| 10. I would like to see the following topics addressed in future Joslin activities: (please choose all that apply)  |                          |                          |                          |                          |
| <input type="checkbox"/> Oral therapy of diabetes <input type="checkbox"/> Use of insulin <input type="checkbox"/> Thyroid disease  |                          |                          |                          |                          |
| <input type="checkbox"/> Lipid disorders <input type="checkbox"/> Intensive insulin therapy <input type="checkbox"/> Osteoporosis   |                          |                          |                          |                          |
| <input type="checkbox"/> Hypertension <input type="checkbox"/> Diabetic nephropathy <input type="checkbox"/> Erectile dysfunction   |                          |                          |                          |                          |
| <input type="checkbox"/> Vascular health <input type="checkbox"/> Diabetic foot problems <input type="checkbox"/> Mental health issues in diabetes  |                          |                          |                          |                          |
| <input type="checkbox"/> Stroke <input type="checkbox"/> Diabetic neuropathy <input type="checkbox"/> Patient adherence   |                          |                          |                          |                          |
| <input type="checkbox"/> Cardiovascular complications <input type="checkbox"/> Diabetic eye disease <input type="checkbox"/> Type 2 diabetes in children  |                          |                          |                          |                          |
| <input type="checkbox"/> Obesity <input type="checkbox"/> Women and diabetes <input type="checkbox"/> Diabetes and heart failure  |                          |                          |                          |                          |
| <input type="checkbox"/> Other: _____   |                          |                          |                          |                          |
| 11. Regarding your use of Web-based activities to earn CME credits:   |                          |                          |                          |                          |
| <input type="checkbox"/> I use the Web frequently to earn CME credits and would continue to use it often or increase use  |                          |                          |                          |                          |
| <input type="checkbox"/> I use the Web occasionally to earn CME credits and am interested in increasing use   |                          |                          |                          |                          |
| <input type="checkbox"/> I use the Web occasionally to earn CME credits and am not interested in increasing use   |                          |                          |                          |                          |
| <input type="checkbox"/> I do not use the Web to earn CME credits but am interested in using it   |                          |                          |                          |                          |
| <input type="checkbox"/> I do not currently use the Web to earn CME credits and am not interested in using it   |                          |                          |                          |                          |
| 12. Answer this question only if you have participated in Web-based CME:  |                          |                          |                          |                          |
| A. What Web sites have you used to obtain CME credit? (choose all that apply)   |                          |                          |                          |                          |
| <input type="checkbox"/> Medical associations <input type="checkbox"/> Commercial CME portal sites  |                          |                          |                          |                          |
| <input type="checkbox"/> Academic/research institutions <input type="checkbox"/> Government Agencies  |                          |                          |                          |                          |
| <input type="checkbox"/> Professional organizations/medical societies <input type="checkbox"/> Medical journals' Web sites  |                          |                          |                          |                          |
| <input type="checkbox"/> Other: Please specify: _____   |                          |                          |                          |                          |
| B. Have you participated in a Web-based CME activity on Joslin's Professional Education Web site at <a href="http://www.professionaled.joslin.org">www.professionaled.joslin.org</a> ?                                |                          |                          |                          |                          |
| <input type="checkbox"/> Yes <input type="checkbox"/> No, not aware it existed <input type="checkbox"/> No, but am aware it exists  |                          |                          |                          |                          |
| C. Which of the following Web-based CME activity formats do you prefer? (choose all that apply)   |                          |                          |                          |                          |
| <input type="checkbox"/> Text-only <input type="checkbox"/> Text with slides <input type="checkbox"/> Slides with audio <input type="checkbox"/> Slides with video <input type="checkbox"/> Interactive               |                          |                          |                          |                          |
| <input type="checkbox"/> Other: Please specify: _____   |                          |                          |                          |                          |
| 13. Any other general comments about the activity:  |                          |                          |                          |                          |

# CE CREDIT APPLICATION & EVALUATION FORM

NAME (First MI Last) <i>Please print clearly</i>	Specialty	Date Completed
Facility Name	SSN (for internal tracking only)	
Facility Address	Daytime Phone	Fax Number
City, State, Zip	Email Address	

## Diabetic Neuropathies: Current Treatment: Strategies

Program Title

Length of time to complete program: \_\_\_\_\_

Did you watch the program: ☐ Via Satellite ☐ In a Group EDA# 556-0040  
☐ On Videocassette ☐ Alone EDA# 556-0040-05

License Number	Discipline Code	Position Code	Participant's Signature
VERY IMPORTANT	See instructions on next page		To verify your attendance

## POST TEST RESPONSES (Test may have fewer than 10 questions.)

- |          |           |
|----------|-----------|
| 1. _____ | 6. _____  |
| 2. _____ | 7. _____  |
| 3. _____ | 8. _____  |
| 4. _____ | 9. _____  |
| 5. _____ | 10. _____ |

Minimum score of 70% required to pass and receive CE credit.

## PARTICIPANT EVALUATION - Please circle the response that matches your opinion about this program:

	Strongly Agree	Agree	Disagree	Strongly Disagree	
1. The educational objectives were met (see page 2 of syllabus):					
Objective #1	4	3	2	1	N/A
Objective #2	4	3	2	1	N/A
Objective #3	4	3	2	1	N/A
Objective #4	4	3	2	1	N/A
2. The educational objectives were related to the overall purpose.	4	3	2	1	N/A
3. The presenter(s) demonstrated expertise in the subject matter (see page 4 of syllabus):					
Presenter #1	4	3	2	1	N/A
Presenter #2	4	3	2	1	N/A
Presenter #3	4	3	2	1	N/A
4. The instructional process (teaching strategy) was of high quality.	4	3	2	1	N/A
5. The activity was fair, balanced, and free of commercial bias.	4	3	2	1	N/A
6. The physical facilities were appropriate (if applicable).	4	3	2	1	N/A
7. The activity enhanced my professional effectiveness.	4	3	2	1	N/A
8. The topics were current and relevant to my practice.	4	3	2	1	N/A
9. The supplemental written materials were useful.	4	3	2	1	N/A
10. Overall, the activity was effective and met my expectations.	4	3	2	1	N/A

Comments/Future Topics: \_\_\_\_\_

Please fax completed form to: **972.309.4580**

or mail to: **PRIMEDIA Healthcare**  
**4101 International Parkway**  
**Carrollton, TX 75007**

Questions: **888.466.3250**

## *Diabetic Neuropathies: Current Treatment Strategies*

## DISCIPLINE CODES INSTRUCTIONS

Some of our programs are accredited for more than one discipline. To ensure that we issue each participant a certificate by the appropriate accrediting body, we ask that you supply us with the following information:

1. The two-digit discipline code    EXAMPLE - for medical doctor:        **1**              **0**              **M**              **D**

2. Followed by the position code    \_\_\_\_\_

DISCIPLINE	DISCIPLINE CODE	POSITION CODE	POSITION
Physician (CME)	10	DO	Doctor of Osteopathy
	40	MD	Medical Doctor
		OP	Other Medical Professional
Administrator	12	HA ADM OA	Hospital Administrator LTC Administrator Other Administrator
Pharmacy	13	PH PA	Pharmacist (Pharm D) Pharmacy Technician
Dietitian	14	RD DTR	Registered Dietitian Dietetic Technician
Dietary Manager	15	DOD	Dietary Manager
Counseling	16	MHC  SW OCT	Mental Health Counselor  Social Worker Other Counselor/Therapist
Laboratory	17	LT	Laboratory Technician/Prof.
Physical Therapy	18	PT PTA	Physical Therapist Physical Therapy Assistant
Occupational Therapy	19	OT  OTA	Occupational Therapist Occupational Therapy Assistant
Respiratory Therapy	20	RT	Respiratory Therapist
Medical Records	21	RHA  RHT  CCS CCP	Health Information Administrator Health Information Technician Coding Specialist Coding Specialist, Physician-based

DISCIPLINE	DISCIPLINE CODE	POSITION CODE	POSITION
Radiology	22	RAD	Radiologic Technologist
Sonography	23	MS	Medical Sonographer
Athletic Trainer	24	AT	Athletic Trainer
Healthcare Quality	25	HQP	Healthcare Quality Professional
Activity Professional	26	ADP	Professional Activity Director
		ADC	Activity Director
		AAC	Activity Assistant
		ACC	Activity Consultant
Nurse (CNE)	30	RN	Registered Nurse
		NP	Nurse Practitioner
		LPN	Licensed Practical Nurse (or LVN)
		CNA	Certified Nursing Assistant
		ON	Other Nursing Professional
Psychology	33	PSY	Psychologist (non-MD)
Case Managers	35	CCM	Certified Case Manager
Certified Nursing Assistant	45	CAN	Certified Nursing Assistant
Emergency	46	EMS	Emergency Medical
Medical Services			Services
Health Unit Coordinator	55	CHUC	Certified Health Unit Coordinator
Other	27	OTH	Other (please indicate)